Insight数据库显示,2025年上半年全球有近1200款新药进展发生变化。其中,59款新药首次成功斩获监管机构批准,步入了商业化阶段;另外还有52款递交了上市申请,超过100款新药顺利迈入临床III期阶段。(数据统计截止至 6 月 29 日,具体说明见图下标)从研发机构来看,恒瑞凭借42款新药发生进展的绝对数量优势,登顶第一,继续断层领先。辉瑞、阿斯利康、诺华、石药则紧随其后,排名前五。...
Source LinkInsight数据库显示,2025年上半年全球有近1200款新药进展发生变化。其中,59款新药首次成功斩获监管机构批准,步入了商业化阶段;另外还有52款递交了上市申请,超过100款新药顺利迈入临床III期阶段。(数据统计截止至 6 月 29 日,具体说明见图下标)从研发机构来看,恒瑞凭借42款新药发生进展的绝对数量优势,登顶第一,继续断层领先。辉瑞、阿斯利康、诺华、石药则紧随其后,排名前五。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.